The ESMO Breast Cancer Virtual Meeting took place from 5–8 May 2021. Global experts in the breast cancer field came together online to present on the most recent advances, including updates from immunotherapy trials and the latest novel therapeutic targets.
View all videos

ESMO Breast 2021

The European School of Medical Oncology Breast Cancer Virtual Congress 2021
05–08 May 2021 | Virtual Meeting
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More

ESMO Breast 2021

The European School of Medical Oncology Breast Cancer Virtual Congress 2021
05–08 May 2021 | Virtual Meeting
The ESMO Breast Cancer Virtual Meeting took place from 5–8 May 2021. Global experts in the breast cancer field came together online to present on the most recent advances, including updates from immunotherapy trials and the latest novel therapeutic targets.
View all videos
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More

Latest videos from ESMO Breast 2021

View all
3:22
PTEN protein and gene expression as a biomarker in breast cancer
Nicola Fusco • 13 May 2021
3:15
Brain metastases in HER2+ breast cancer
Volkar Mueller • 12 May 2021
2:38
Potential new drugs with activity in metastatic TNBC
Javier Cortés • 12 May 2021
5:55
Decision-making in metastatic HER2+ breast cancer
Lisa Carey • 29 Apr 2021

TNBC

View all
1:51
Optimal chemotherapy combinations in TNBC gBRCA subtypes
Sung-Bae Kim • 4 May 2021
5:53
Treating early-stage TNBC
Rebecca Dent • 29 Apr 2021
1:25
Dato-DXd: a new ADC on the block
Sara Tolaney • 12 May 2021
2:57
IO-IO combinations in metastatic TNBC
Marleen Kok • 12 May 2021

Metastatic Breast Cancer

View all
1:39
Abemaciclib for HR+/HER2- advanced or metastatic breast cancer
Ahmad Awada • 6 May 2021
2:10
Treating CNS metastases in HER2+ breast cancer
Thomas Bachelot • 21 Apr 2021
1:56
Treating HER2+ breast cancer with brain metastases
Erika Hamilton • 11 May 2021
7:16
E-cadherin inactivation by Trop-2 drives metastases in TNBC
Saverio Alberti • 21 Apr 2021

Immuno-Oncology

View all
4:08
ROSALINE: targeting ROS1 in combination with ET for breast cancer
Elisa Agostinetto • 20 Apr 2021
4:01
Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?
Paolo Tarantino • 27 Apr 2021
1:25
Dato-DXd: a new ADC on the block
Sara Tolaney • 12 May 2021
6:51
ADCs for HER2+ and HER2-low breast cancer
Rupert Bartsch • 11 May 2021

Breast Cancer Podcasts

Sequencing HER2-targeting therapies in the metastatic breast cancer space
The Breast Cancer Sessions: a focus on the St. Gallen Consensus
Predictive and prognostic biomarkers in breast cancer
SABCS 2020 highlights: immunotherapy, novel agents & trial updates
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals